Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV-Reference-Cited by-同舟云学术

Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV

Published:2023-06-15 Issue:3 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Verburgh Myrthe L.¹²³⁴^ORCID,van Pul Lisa²⁵,Grobben Marloes²⁶,Boyd Anders⁷⁸,Wit Ferdinand W. N. M.¹²⁷,van Nuenen Ad C.²⁵,van Dort Karel A.²⁵,Tejjani Khadija²⁶,van Rijswijk Jacqueline²⁶,Bakker Margreet²⁶,van der Hoek Lia²⁶^ORCID,Schim van der Loeff Maarten F.¹²⁸,van der Valk Marc¹²⁷,van Gils Marit J.²⁶^ORCID,Kootstra Neeltje A.²⁵,Reiss Peter¹²⁴⁹,Reiss P.,Wit F. W. N. M.,van der Valk M.,Boyd A.,Verburgh M. L.,van der Wulp I. A. J.,Vanbellinghen M. C.,van Eeden C. J.,Schim van der Loeff M. F.,Koole J. C. D.,del Grande L.,Agard I.,Zaheri S.,Hillebregt M. M. J.,Ruijs Y. M. C.,Benschop D. P.,el Berkaoui A.,Boyd A.,Wit F. W. N. M.,Kootstra N. A.,Harskamp-Holwerda A. M.,Maurer I.,Mangas Ruiz M. M.,Boeser-Nunnink B. D. N.,Starozhitskaya O. S.,van der Hoek L.,Bakker M.,van Gils M. J.,Dol L.,Rongen G.,Geerlings S. E.,Goorhuis A.,Hovius J. W. R.,Nellen F. J. B.,Prins J. M.,van der Poll T.,van der Valk M.,Wiersinga W. J.,van Vugt M.,de Bree G.,Lemkes B. A.,Spoorenberg V.,Wit F. W. N. M.,van Eden J.,Pijnappel F. J. J.,Weijsenfeld A.,Smalhout S.,Hylkema-van den Bout I. J.,Bruins C.,Spelbrink M. E.,Postema P. G.,Bisschop P. H. L. T.,Dekker E.,van der Velde N.,Franssen R.,Willemsen J. M. R.,Vogt L.,Portegies P.,Geurtsen G. J.,Visser I.,Schadé A.,Nieuwkerk P. T.,van Steenwijk R. P.,Jonkers R. E.,Majoie C. B. L. M.,Caan M. W. A.,van den Born B. J. H.,Stroes E. S. G.,van Oorspronk S.

Affiliation:

1. Amsterdam UMC, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands

2. Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands

3. Amsterdam Public Health, Global Health, Amsterdam, The Netherlands

4. Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

5. Amsterdam UMC, University of Amsterdam, Experimental Immunology, Amsterdam, The Netherlands

6. Amsterdam UMC, University of Amsterdam, Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam, The Netherlands

7. HIV Monitoring Foundation, Amsterdam, The Netherlands

8. Public Health Service of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands

9. Amsterdam UMC, University of Amsterdam, Global Health, Amsterdam, The Netherlands

Abstract

Some studies have suggested that people with HIV may respond less well to vaccines against SARS-CoV-2. We comprehensively compared B- and T-cell responses to different COVID-19 vaccines in middle-aged persons with well-treated HIV and individuals of the same age without HIV, who were also highly comparable in terms of demographics and lifestyle, including those with prior SARS-CoV-2 infection.

Funder

ViiV Healthcare

ZonMw

Aids Fonds

Gilead Sciences

Auris | J&J | Janssen Pharmaceuticals

Merck & Co. | Merck Sharp and Dohme

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link